Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
AbCellera reports earnings after market close, meaning Day 0 reflects anticipation and any after-hours reaction, while Day +1 captures the first full trading session following results.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-05 | -$0.17 (-2.79%) | $0.37 (6.08%) | +$0.61 (+10.30%) | $0.95 (15.96%) |
| 2026-05-11 | +$0.01 (+0.19%) | $0.39 (7.44%) | -$0.30 (-5.71%) | $0.53 (10.10%) |
| 2026-02-24 | +$0.19 (+6.27%) | $0.21 (6.93%) | -$0.03 (-0.93%) | $0.26 (7.92%) |
| 2025-11-06 | -$0.16 (-3.41%) | $0.34 (7.25%) | -$0.62 (-13.69%) | $0.59 (13.02%) |
| 2025-08-07 | +$0.12 (+2.91%) | $0.23 (5.58%) | +$0.01 (+0.24%) | $1.08 (25.47%) |
| 2025-05-08 | +$0.00 (+0.00%) | $0.08 (3.98%) | +$0.02 (+1.00%) | $0.19 (9.45%) |
| 2025-02-27 | +$0.00 (+0.00%) | $0.13 (4.62%) | -$0.33 (-11.47%) | $0.41 (14.04%) |
| 2024-11-04 | +$0.16 (+5.86%) | $0.18 (6.59%) | -$0.17 (-5.88%) | $0.29 (10.03%) |
| Avg Abs Move | 2.68% | 6.06% | 6.15% | 13.25% |
Historically, AbCellera has exhibited significant post-earnings volatility, with an average absolute Day 0 move of 2.68% and a Day +1 move of 6.15%. The Day +1 range averages 13.25%, indicating that the stock often experiences wide intraday swings as investors digest results and management commentary.
Recent quarters show mixed directional patterns. The most recent earnings (August 2026) saw a Day 0 decline of 2.79%, followed by a sharp 10.30% rally on Day +1, likely driven by the simultaneous release of positive ABCL635 Phase 2 data. In May 2026, the stock was essentially flat on Day 0 (+0.19%) but declined 5.71% on Day +1. The February 2026 report triggered a 6.27% Day 0 gain, though Day +1 was flat. The November 2025 report saw a 3.41% Day 0 decline followed by a steep 13.69% drop on Day +1—the largest recent move.
The data suggests that investors should brace for potential double-digit percentage swings in the session following earnings, particularly if management provides updates on ABCL635 Phase 3 timelines, 12-week durability data, or new partnership activity. The stock's sensitivity to clinical and partnership news makes it prone to outsized reactions relative to the earnings print itself.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 14) |
| Expected Move | $1.77 (14.87%) |
| Expected Range | $10.12 to $13.66 |
| Implied Volatility | 125.95% |
The options market is pricing a 14.87% expected move by the November 20 expiration (14 days out), with an implied range of $10.12 to $13.66. This is notably higher than the historical average Day +1 move of 6.15%, but well within the historical Day +1 range of 13.25%. The elevated expected move likely reflects heightened uncertainty around management's commentary on ABCL635 Phase 3 plans, potential updates on 12-week durability data, and the financial impact of the Jazz partnership. Given the stock's history of double-digit post-earnings swings—particularly the 10.30% Day +1 rally in August and the 13.69% Day +1 decline in November 2025—the options market appears to be pricing in a realistic range of outcomes.
Part 3: What Analysts Are Saying
Current Analyst Consensus
AbCellera commands strong support from the analyst community, with 12 Strong Buy ratings, 0 Moderate Buys, and 2 Hold ratings out of 14 total recommendations. The average recommendation of 4.71 (on a 5-point scale where 5 = Strong Buy) reflects overwhelmingly bullish sentiment. The consensus price target sits at $17.17, implying 44.5% upside from the current price of $11.88. Targets range from a low of $9.00 to a high of $30.00, indicating significant dispersion in views on the company's long-term potential.
Sentiment Evolution
Analyst sentiment has improved over the past month. Strong Buy ratings increased from 10 to 12, while the average recommendation ticked up from 4.67 to 4.71. This shift follows the positive ABCL635 Phase 2 data in August and the Jazz Pharmaceuticals partnership announced in June, both of which have reinforced the bull case for AbCellera's platform and pipeline.
Implications for Investors
The consensus price target of $17.17 suggests analysts see substantial upside potential, driven by expectations that ABCL635 will advance into Phase 3 and that the Jazz partnership will generate meaningful milestone revenue. However, the wide range of price targets—from $9.00 to $30.00—underscores the binary nature of the investment thesis. Bulls see a path to best-in-class status in menopause and a validated platform generating multiple clinical candidates; bears worry about execution risk, widening losses, and the long runway to profitability. The improved sentiment trend indicates that recent clinical and partnership wins are shifting the narrative in AbCellera's favor, but the stock remains highly dependent on upcoming catalysts, including 12-week ABCL635 data and Phase 3 trial design.
Part 4: Technical Picture
Barchart Technical Opinion
The Barchart Technical Opinion currently rates AbCellera as a 40% Buy, down from 64% Buy a week ago and 80% Buy a month ago. This represents a notable weakening in technical momentum over the past month, suggesting that near-term bullish conviction has cooled despite the stock's strong year-to-date performance.
Timeframe Analysis
Short-term (Hold): The neutral short-term signal indicates consolidation or indecision in the immediate trading environment, with neither bulls nor bears in clear control heading into earnings.
Medium-term (50% Buy): A moderate buy signal suggests the intermediate trend remains constructive, though not overwhelmingly bullish, reflecting a balance between recent gains and potential resistance levels.
Long-term (100% Buy): The strong long-term buy signal points to sustained upward momentum over a broader timeframe, consistent with the stock's 68.8% gain year-to-date and its position well above the 200-day moving average.
Trend Characteristics
The trend is characterized as Good in strength but Weakest in direction, indicating that while the underlying uptrend remains intact, recent price action has lost momentum and may be vulnerable to near-term volatility or consolidation heading into the earnings release.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $11.72 | 50-Day MA | $12.28 |
| 10-Day MA | $12.25 | 100-Day MA | $10.01 |
| 20-Day MA | $12.18 | 200-Day MA | $7.04 |
Technical Setup Heading into Earnings
AbCellera is trading at $11.88, positioned above its 5-day moving average of $11.72 but below its 10-day ($12.25), 20-day ($12.18), and 50-day ($12.28) moving averages. This suggests the stock has pulled back from recent highs and is testing near-term support. However, it remains well above its 100-day moving average of $10.01 and 200-day moving average of $7.04, confirming the longer-term uptrend is intact.
The technical picture is mixed: while the stock has strong long-term momentum, the recent pullback below key short-term moving averages and the weakening Barchart Opinion signal suggest caution. The 50-day moving average at $12.28 represents immediate resistance, while the 100-day at $10.01 serves as a key support level. Given the stock's history of volatile post-earnings moves and the elevated options expected move of 14.87%, traders should be prepared for a potential breakout above $12.28 on positive news or a retest of $10.01 support if results or guidance disappoint. The overall setup is neither strongly supportive nor cautionary—it's neutral with a bias toward volatility.